Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Published Online: 2020-07-?
Journal: Journal for ImmunoTherapy of CancerLoading...
Authors: Alain Ravaud•Asim Amin•Bernard Escudier•Bohuslav Melichar•Brian I Rini•Camillo Porta•Christian K Kollmannsberger•David F McDermott•Elizabeth R Plimack•Frede Donskov•Hans J Hammers•Howard Gurney•M Brent McHenry•Marc-Oliver Grimm•Nizar M Tannir•Osvaldo Arén Frontera•Pamela Salman•Philippe Barthélémy•Poul F Geertsen•Raya Leibowitz-Amit•Robert J Motzer•Saby George•Scott S Tykodi•Shruti Shally Saggi•Thomas Powles•Toni K Choueiri•Victoria Neiman•Viktor Grünwald•Yoshihiko Tomita
